REGENXBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against REGENXBIO Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against REGENXBIO Inc. for allegedly providing misleading information regarding its gene therapy product RGX-111, leading to significant investor losses [2][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of Maryland on behalf of all individuals and entities who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026 [2]. - Investors have until April 14, 2026, to apply to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that REGENXBIO's management made positive assertions about RGX-111's trial success while concealing material adverse facts regarding its efficacy and safety [3]. - Following the announcement of a clinical hold by the FDA due to the discovery of an intraventricular CNS tumor in a trial participant, REGENXBIO's stock price fell from $13.41 to $11.01, a decline of 17.8% in one day [3]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the case are encouraged to contact the law firm for more details and assistance [4].